ΕΚΠΑ - ΕΛΚΕ

Προκηρύξεις Ερευνητικών Προγραμμάτων


Αρ. Προκ.IMI2-2016-10-03
Ημ. Δημ/σης04/01/2017
Ημ. Λήξης28/03/2017
Περιγραφή Τίτλος: IMI2-2016-10-03 Improving the care of patients suffering from acute or chronic pain

Πρόγραμμα: Horizon 2020
Τύπος πρόσκλησης: Joint Undertaking (JU)
Φορέας Διαχείρισης: Innovative Medicines Initiative (IMI)
Δράση: Innovative Medicines Initiative 2 (IMI2)
Call ID: IMI2-2016-10-03
Action Type: RIA – Research and Innovation Actions

Προθεσμία first stage: 28/3/2017 17:00 Brussels Time / 2nd stage Deadline: 14 September 2017 17:00:00 Brussels Time

Η “Innovative Medicines Initiative” (IMI) είναι η μεγαλύτερη Ευρωπαϊκή πρωτοβουλία σύμπραξης δημόσιου – ιδιωτικού τομέα με σκοπό να επιταχύνει την δημιουργία καλύτερων και ασφαλέστερων φαρμάκων.

Συνοπτικά για την Πρόσκληση
There is a very high need for improving health care for the management of pain, which is the scope of this Topic. As acute and persistent pain of different origin represent common medical, social, and economic burden, and its pharmacotherapy is still an unresolved issue. In order to achieve an optimised management of pain patients and to support the process of decision making in clinical practise, objective assessments of the treatment success are needed. Successful novel approaches for patient stratification could reduce the still high number of non-responders. Developing new analgesics is challenging because promising preclinical data are often not reproduced in the clinic, and often without knowing the reason. Improved pharmaco-dynamic biomarkers could define whether an intended target is adequately engaged, greatly reducing the risk in clinical development of a new drug. Finally, for many pain indications, there are no adequate preclinical models available, precluding preclinical investigations and leaving affected patients with little hope of relief. The goal of this Topic is to make advances in three pain areas in a complementary manner. These three Subtopics, each of which addresses a specific scientific challenge, together offer significant opportunities for cross-fertilisation:

Subtopic 3A: using Patient Reported Outcome Measures to improve the management of acute and chronic pain (PROMs);

Subtopic 3B: improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species (BIOM);

Subtopic 3C: improving translation in chronic pelvic pain (CPP)…
ΦορέαςΕΥΡΩΠΑΪΚΑ ΠΡΟΓΡΑΜΜΑΤΑ
ΚατηγορίαHorizon 2020
Πρόγραμμα 
Τμήματα 
Αρχείο Λήψη
Σύνδεσμος Ιστοσελίδα
 


Προηγούμενη σελίδα